Safety and tolerability of oral lisdexamfetamine in adults with methamphetamine dependence: a phase-2 dose-escalation study.

ABSTRACT:

Objectives

To examine the safety of an agonist-type treatment, lisdexamfetamine (LDX), at 250 mg/day among adults with methamphetamine (MA) dependence.

Design

A dose-escalating, phase-2, open-label, single-group study of oral LDX at two Australian drug treatment services.

Setting

The study was conducted at two Australian stimulant use disorder treatment clinics.

Participants

There were 16 participants: at least 18 years old, MA dependent for at least the preceding 2 years using ICD-10 criteria, reporting use of MA on at least 14 of the preceding 28 days.

Interventions

Daily, supervised LDX of 100-250 mg, single-blinded to dose, ascending-descending regimen over 8 weeks (100-250 mg over 4 weeks; followed by 4-week dose reduction regimen, 250-100 mg). Part

SUBMITTER: Ezard N 

PROVIDER: S-EPMC8137170 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature